LOBEFARO, RICCARDO

LOBEFARO, RICCARDO  

Universita' degli Studi di MILANO  

Mostra records
Risultati 1 - 13 di 13 (tempo di esecuzione: 0.0 secondi).
Titolo Data di pubblicazione Autori Tipo File Abstract
PillarX: A Microfluidic Device to Profile Circulating Tumor Cell Clusters Based on Geometry, Deformability, and Epithelial State 2022 Fardin, AmirGiangreco, GiovanniMarchesi, StefanoVernieri, ClaudioLobefaro, RiccardoSigismund, SaraFiore, Pier Paolo DiScita, Giorgio + Article (author) -
Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial 2022 Ligorio, FrancescaProvenzano, LeonardoLobefaro, RiccardoVingiani, AndreaPruneri, Giancarlode Braud, Filippo + Article (author) -
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology 2022 Manglaviti S.Beninato T.Zattarin E.Lobefaro R.Bottiglieri A.Apollonio G.de Braud F. G. M. + Article (author) -
Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin 2022 Zattarin, EmmaNichetti, FedericoLigorio, FrancescaMazzeo, LauraLobefaro, RiccardoFuca, GiovanniPeverelli, GiorgiaVingiani, Andreade Braud, FilippoVernieri, Claudio + Article (author) -
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers 2021 Lobefaro R.De Braud F. + Article (author) -
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program 2021 Bottiglieri A.Lobefaro R.Nichetti F.Manglaviti S.de Braud F. + Article (author) -
The pan-immune-inflammation-value predicts the survival of patients with human epidermal growth factor receptor 2 (Her2)—positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab 2021 Ligorio F.Zattarin E.Lobefaro R.Zambelli L.Leporati R.de Braud F. + Article (author) -
Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer 2021 Ligorio F.Pellegrini I.Vingiani A.Lobefaro R.Zattarin E.Pruneri G.de Braud F. + Article (author) -
Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma : Myth or Reality? 2020 Pietrantonio FLobefaro R + Article (author) -
Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications 2020 Zattarin, ELeporati, RLigorio, FLobefaro, RVingiani, APruneri, GVernieri, C Article (author) -
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer 2019 Pietrantonio, FilippoLobefaro, RiccardoRaimondi, AlessandraSartore-Bianchi, AndreaLongarini, RaffaellaPetrelli, FaustoRandon, GiovanniPagani, FilippoFucà, Giovannide Braud, Filippo + Article (author) -
The landscape of actionable gene fusions in colorectal cancer 2019 Randon G.Prisciandaro M.Lobefaro R.de Braud F.Pietrantonio F. + Article (author) -
“Systemic strategy at the patient’s service”: A congress report on supportive care in oncology 2017 NichettiFederico; LobefaroRiccardo; PaganiFilippo; RandonGiovanni; CortiFrancesca; De Braud + Article (author) -